Celecoxib Treatment for Lung Cancer

Withdrawn before enrolling · Phase 1

Conditions studied: Non-Small-Cell Lung Carcinoma

In brief

This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.

Key facts

Study ID

NCT00108186

Run by

US Department of Veterans Affairs

People needed

0

Starts

2004-10-01

Expected to finish

2011-06-01

Last updated by the study team

2014-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy

You may not qualify if…

• Hypersensitivity to celecoxib or NSAIDs, previous history of GI bleeding or ulceration, chronic or concurrent use of steroids and renal insufficiency

Where it is running

• VA Greater Los Angeles Healthcare System, West LA — West Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.